Search hospitals

>

Texas

>

Dallas

Baylor University Medical Center

Claim this profile

Dallas, Texas 75246

Global Leader in Multiple Myeloma

Global Leader in Acute Myeloid Leukemia

Conducts research for Breast Cancer

Conducts research for Heart Failure

Conducts research for Acute Myelogenous Leukemia

357 reported clinical trials

17 medical researchers

Photo of Baylor University Medical Center in DallasPhoto of Baylor University Medical Center in DallasPhoto of Baylor University Medical Center in Dallas

Summary

Baylor University Medical Center is a medical facility located in Dallas, Texas. This center is recognized for care of Multiple Myeloma, Acute Myeloid Leukemia, Breast Cancer, Heart Failure, Acute Myelogenous Leukemia and other specialties. Baylor University Medical Center is involved with conducting 357 clinical trials across 596 conditions. There are 17 research doctors associated with this hospital, such as Joyce O'Shaughnessy, MD, Carlos R Becerra, Susan Mathai, MD, and Andrew S Paulson, MD.

Area of expertise

1

Multiple Myeloma

Global Leader

Baylor University Medical Center has run 22 trials for Multiple Myeloma. Some of their research focus areas include:

Stage III
del(17/17p) positive
t(14;16) positive
2

Acute Myeloid Leukemia

Global Leader

Baylor University Medical Center has run 22 trials for Acute Myeloid Leukemia. Some of their research focus areas include:

KMT2A positive
NPM1 positive
HA-1 positive

Top PIs

Clinical Trials running at Baylor University Medical Center

Acute Myeloid Leukemia

Idiopathic Pulmonary Fibrosis

Lymphoma

Non-Hodgkin's Lymphoma

Interstitial Lung Disease

Multiple Myeloma

Post-Traumatic Stress Disorder

Heart Failure

Pulmonary Hypertension

Crohn's Disease

Image of trial facility.

Experimental Drug

for Leukemia Post-Stem Cell Transplant

This is a multi-center, non-randomized, concurrent controlled, multi-arm, Phase 1 interventional, open-label, biologic assignment-based umbrella study evaluating the feasibility, safety and preliminary efficacy of an escalating dose regimen of up to 2 doses of TSC-100 and TSC-101 in patients with AML, MDS, or ALL following HCT from a haploidentical donor, MMUD, or MUD

Recruiting

1 award

Phase 1

Image of trial facility.

JNJ-75276617

for Acute Leukemia

This trial tests JNJ-75276617, an oral drug designed to block a protein interaction that helps leukemia cells grow. It targets patients with specific genetic types of AML or ALL. By stopping these proteins from working together, the drug aims to slow down or stop cancer cell growth.

Recruiting

1 award

Phase 1 & 2

6 criteria

Image of trial facility.

SEA-CD70

for Myelodysplastic Syndrome and Acute Myeloid Leukemia

This trial is testing a new drug, SEA-CD70, alone and with azacitidine, to see if it is safe and works for adults with certain blood cancers that haven't responded to other treatments. The study will determine the best dose and check for side effects. Azacitidine is a treatment that improves survival, reduces the need for transfusions, and lowers the risk of progression to acute myeloid leukemia in patients with higher risk myelodysplastic syndromes.

Recruiting

1 award

Phase 1

10 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Baylor University Medical Center?

Where is Baylor University Medical Center located?

Who should I call to ask about financial aid or insurance network?

What insurance does Baylor University Medical Center accept?

What awards or recognition has Baylor University Medical Center received?